Gallium-68 (Ga-68) is a generator-produced positron-emitting radionuclide with a physical half-life of approximately 68 minutes, making it exceptionally well-suited for rapid, high-resolution PET imaging of receptor-targeted peptides and small molecules. Protheragen delivers end-to-end Ga-68 radiolabeling solutions—from precursor design and chelator conjugation to automated synthesis, quality control, and regulatory documentation—empowering your radiopharmaceutical pipeline from bench to bedside.
Gallium-68 (⁶⁸Ga, t₁/₂ ≈ 68 min, Eβ⁺max = 1.9 MeV) is obtained from a ⁶⁸Ge/⁶⁸Ga generator system, eliminating the need for an on-site cyclotron and enabling decentralized production of PET radiopharmaceuticals. The radionuclide exhibits favorable coordination chemistry, particularly with macrocyclic bifunctional chelators such as DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid), which form thermodynamically stable and kinetically inert complexes suitable for in vivo administration. The short half-life of Ga-68 aligns pharmacokinetically with small peptides and low-molecular-weight ligands, enabling rapid blood clearance, high target-to-background contrast, and same-day imaging protocols that are both patient-friendly and logistically efficient.
Fig 1. Typical positive findings of ⁶⁸Ga-PSMA-11 PET/CT in M0 CRPC patients. (Fourquet, Aloÿse, et al., 2020)
The radiolabeling process typically involves elution of ⁶⁸Ga³⁺ from the generator, purification via cation-exchange solid-phase extraction (SCX) to remove ⁶⁸Ge breakthrough and metallic impurities, and chelation with the DOTA- or NOTA-conjugated precursor under optimized pH (3–4) and temperature (85–95 °C) conditions. Modern NaCl-based elution methods have replaced organic solvent-dependent protocols, yielding radiochemical purity exceeding 95% within 12–16 minutes and enabling direct patient administration without residual solvent determination. These advances have catalyzed the clinical translation of ⁶⁸Ga-labeled agents for neuroendocrine tumors, prostate cancer, and an expanding array of oncological and inflammatory indications.
| Category | Key Developments | Clinical / Scientific Impact |
|---|---|---|
| Approved / Late-Stage Agents | [⁶⁸Ga]Ga-PSMA-11 (approved for prostate cancer); [⁶⁸Ga]Ga-DOTATATE / DOTATOC / DOTANOC (NET imaging); [⁶⁸Ga]Ga-FAPI-04/46 (fibroblast activation protein imaging) | Established standard-of-care for PSMA-positive lesion detection, NET staging, and tumor microenvironment characterization across multiple solid malignancies. |
| Theranostic Pairs | Ga-68 (diagnostic) paired with Lu-177 or Ac-225 (therapeutic) using identical targeting vectors (e.g., PSMA, SSTR, FAPI) | Enables personalized patient selection for radioligand therapy (RLT), real-time dosimetry, and treatment response monitoring via matched diagnostic and therapeutic chemistry. |
| Novel Targets & Vectors | B7-H3 bicyclic peptides, RGD integrin αvβ3 ligands, melanocortin-1 receptor (MC1R) analogues, bombesin receptor ligands | Expands PET imaging into rare cancers, pediatric oncology, and inflammatory diseases; supports precision medicine through receptor-density quantification. |
| Radiochemistry Innovations | NaCl-based cationic elution (solvent-free); automated synthesis modules; click-chemistry bioconjugation; DOTA-Mal site-specific labeling | Reduces synthesis-to-release time to <20 min; eliminates organic solvent residual testing; improves reproducibility and quality compliance for clinical batches. |
| Regulatory & Market Trends | Special approval designations; priority eligibility; rare disease incentives; expanded reimbursement in major markets | Accelerates clinical translation; reduces time-to-market; fosters investment from major pharma and biotech startups. |
| Preclinical & IIT Ecosystem | Micro-PET/CT imaging in rodent tumor models; ex vivo autoradiography; biodistribution and pharmacokinetic studies; blocking experiments for specificity validation | Provides robust proof-of-concept data for clinical trial packages; de-risks clinical development by validating target engagement and off-tissue distribution in vivo. |
At Protheragen, we recognize that the success of a Ga-68 radiopharmaceutical hinges on the seamless integration of radiochemical expertise, analytical rigor, and regulatory foresight. Our multidisciplinary team combines deep knowledge of generator-based isotope handling, bifunctional chelator chemistry, and automated synthesis with a robust quality management system designed to support both preclinical discovery programs and IIT clinical studies. Whether you are optimizing a novel DOTA-conjugated peptide for first-in-human imaging or scaling a validated tracer toward compliant production, Protheragen provides the technical infrastructure and scientific partnership to accelerate your development timeline.
We design and synthesize DOTA-, NOTA-, NODAGA-, and DFO-conjugated precursors tailored to your biological target. Our team optimizes chelator-to-peptide ratios, linker length, and hydrophilicity to maximize radiolabeling efficiency and in vivo stability.
Utilizing pharmaceutical-grade ⁶⁸Ge/⁶⁸Ga generators, we perform cation-exchange purification (SCX cartridge) to isolate high-specific-activity ⁶⁸Ga³⁺, removing ⁶⁸Ge breakthrough, iron, and other metallic contaminants that compromise labeling yield.
We offer both manual hot-cell synthesis for exploratory chemistry and fully automated module-based production for reproducible, quality-aligned batch manufacturing with radiochemical purity >95%.
We conduct in vitro cell-binding assays, in vivo micro-PET/CT imaging, ex vivo autoradiography, and pharmacokinetic profiling in rodent tumor models to validate target specificity, tumor-to-background ratios, and metabolic stability of your Ga-68 tracer.
From investigator-brochure preparation and ethics committee documentation to on-site radiopharmacy training and batch release protocols, we guide your Ga-68 agent through the regulatory pathway required for first-in-human and early-phase clinical trials.
We evaluate radiolytic stability, shelf-life under various buffer conditions, and formulation optimization (e.g., ascorbic acid as radical scavenger) to extend the usable lifetime of your Ga-68 product beyond the isotope's physical half-life constraints.
Our Ga-68 radiolabeling workflow is designed to maximize radiochemical yield, minimize synthesis time, and ensure full traceability from generator elution to final product release. The entire process, from elution to QC completion, is typically accomplished within 20–30 minutes, aligning with the short half-life of ⁶⁸Ga and the logistical demands of clinical PET imaging.
Step 1: Project Consultation & Precursor Evaluation
We begin with a detailed consultation to understand your target biology, desired pharmacokinetics, and regulatory objectives. Our chemists evaluate your precursor's chelator compatibility (DOTA vs. NOTA vs. alternative frameworks) and conduct feasibility labeling experiments to establish optimal reaction conditions.
Step 2: ⁶⁸Ga Elution & Cation-Exchange Purification
The ⁶⁸Ge/⁶⁸Ga generator is eluted with dilute HCl, and the eluate is passed through a preconditioned strong cation-exchange (SCX) cartridge to trap ⁶⁸Ga³⁺. Metallic impurities and ⁶⁸Ge breakthrough are washed away, leaving purified ⁶⁸Ga ready for high-specific-activity labeling.
Step 3: Radiolabeling Reaction & Optimization
Purified ⁶⁸Ga is eluted into a reaction vial containing the DOTA- or NOTA-conjugated precursor dissolved in sodium acetate buffer (pH 3.5–4.5). The mixture is incubated at 85–95 °C for 8–12 minutes, with real-time optimization of precursor mass, buffer concentration, and reaction time to achieve >95% incorporation.
Step 4: Neutralization, Sterile Filtration & Formulation
The reaction mixture is neutralized to physiological pH (6–7) using phosphate buffer, passed through a 0.22 μm sterile filter, and formulated in isotonic saline or other vehicle as specified. Ascorbic acid or ethanol may be added as radioprotectants depending on the tracer's stability profile.
Step 5: Quality Control & Batch Release
Comprehensive QC is performed including radio-TLC/HPLC for radiochemical purity, pH measurement, radionuclidic identity via half-life determination, and endotoxin screening. Batches meeting all predefined acceptance criteria are released with full documentation for preclinical or clinical use.
Step 6: Preclinical Validation or Clinical Translation
For preclinical programs, we proceed with in vitro binding assays and in vivo imaging studies to validate biological performance. For clinical-bound agents, we compile chemistry-manufacturing-control packages, stability data, and radionuclide dosimetry estimates to support clinical trial applications.
Ready to advance your Ga-68 radiopharmaceutical from concept to clinic? Whether you need a one-time radiolabeling batch for preclinical imaging or a long-term partnership for clinical radiopharmaceutical development, Protheragen is here to help. Reach out to us today to discuss your project requirements, and our radiochemistry specialists will craft a tailored solution that aligns with your scientific goals and regulatory timeline. Contact us now to schedule a consultation and discover how Protheragen can accelerate your journey in precision nuclear medicine.
Reference